Recently, a ccRCC proteomic study reported that the PI3K/AKT/mTOR pathway was the resistance mechanism of sunitinib treatment in ccRCC patients, and the Warburg effect derived from VHL mutations can further enhance TKI resistance in ccRCC [9]. Here, MTOR is linked to nonpapillary renal cell carcinoma.